3Chung MK,Martin DO,Sprecher D,et al.C-reactive protein elevation in patients with atrial arrhythmias:inflammatory mechanisms and persistence of atrial fi-brillation.Circulation,2001,104:2886-2891.
二级参考文献10
1Frustaci A,Chimenti C,Bellocci F,et al.Histological substrate of atrial biopsies in patients with lone atrial fibrillation.Circulation,1997,96:1180-1184.
2Aviles RJ,Martin DO,Hassen CA,et al.Inflammation as a risk factor for atrial fibrillation.Circulation,2003,108:3006-3010.
3Scalia R,Gooszen ME,Jones SP,et al.Simvastatin exerts both anti-imflammatory and cardioprotective.Effects in apolipoprotein E-deficient mice.Circulation,2001,103:2598-2603.
4van de Ree MA,Huisman MV,Princen HMG,et al.Strong decrease of high sensitivity C-reactive protein with high-dose atovastatin in patients with type 2 diabetes mellitus.Atherosclerosis,2003,166:129-135.
5Li D,Fareh S,Leung TK,et al.Promotion of atrial fibrillation by heart failure in dog:atrial remodeling of a different sort.Circulation,1999,100:87-95.
6Mihm MJ,Yu F,Cames CA,et al.Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation.Circulation,2001,104:174-180.
7Chung MK,Martin DO,Sprecher D,et al.C-reactive protein elevation in patients with atrial arrhythmias.Circulation,2001,104:2886-2891.
8Lefer AM,Campbell B,Shin YK,et al.Simvastatin preserves the ischemic-reperfused myocardium in normocholerterolemic rat hearts.Circulation,1999,100:178-184.
9Xu YY,Jabbour S,Goldberg k,et al.Usefulness of station drugs in protecting against atrial fibrillation in patients with CorOnary artery disease.Am J Cardiol,2003,92:1379-1383.
10Gómez-Gerique JA,Ros Z,Olován J,et al.Effect of atorvastatin and bezafibrate on plasma levels of C-reactive protein in combined (mixed) hyperlipidemia.Atherosclerosis,2002,162:245-251.
2Hohnloser SH,Kuck KH,LilienthaI J.Rhythm or rate control in at-rial fibrillation-pharmacological intervention in atrial fibrillation(PIAF);a randomised trial[J].Lancet,2000,356(9244):1789-1794.
3Jadad AR,Moore RA,Carroll D,et al.Assessing the quality of re-ports of randomized clinical trials:is blinding necessary[J].Con-trol Clin Trials,1996,17(1):1-12.
4Fmstaci A,Chimenti C,Bellocci F,et al.Histological substrate ofatrial biopsies in patients with lone atrial fibrillation[J].Circula-tion,1997,96(4):1180-1184.
6Korantzopoulos P,Kolettis T,Siogas K,et al.Atrial fibrillation andelectrical remodeling:the potential role of inflamma-tion and oxida-tive stress[J].Med Sci Monit,2003,9(9):225-229.
7Liu T,Li G,Li L,et al.Association between C-reactive protein andrecurrence of atrial fibrillation after successful electrical cardiover-sion:a meta-analysis[J].J Am Coll Cardiol,2007,49(15):1642-1648.
8Chung MK,Martin DO,Sprecher D,et al.C-reactive protein eleva-tion in patients with atrial arrhythmias:inflammatory mechanismsand persistence of atrial fibrillation[J].Circulation,2001,104(24):2886-2891.
9Mam F,Pascual DA,Roldan V,et al.Statins and postoperative riskof atrial fibrillation following coronaiy artery bypass grafting[J].Am J Cardiol,2006,97(1):55-60.
10Cardin S,Li D,Thorin-Trescases N,et al.Evolution of the atrial fi-brillation substrate in experimental congestive heart failure:angio-tensin-dependent and-independent pathways[J].Cardiovasc Res,2003,60(2);315-325.
